Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 3, Issue 6, 2022

Research Progress of ACSLs and Breast Cancer

Download as PDF

DOI: 10.23977/medsc.2022.030617 | Downloads: 7 | Views: 447

Author(s)

Hua Liu 1, Jianfeng Quan 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China
2 Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Hua Liu

ABSTRACT

Long-chain acyl-CoA synthase (ACSL) is a key enzyme that catalyzes the activation of fatty acids and plays an important role in the metabolism of fatty acids. ACSL includes five different subtypes, and the expression of a single ACSL subtype can change the distribution and quantity of fatty acids in cells, which in turn will change the expression of ACSLs in cells. ACSL is abnormally expressed in many types of tumors, and has complex functions in promoting tumor cell proliferation or apoptosis and affecting tumor progression. ACSL regulates tumor progression through different signal transduction pathways and molecular mechanisms, and its abnormal expression has certain influence on tumor differentiation, tumor prognosis and recurrence, which is expected to become a new marker and therapeutic target. In recent years, the incidence and mortality of breast cancer have increased significantly, and breast cancer patients in China are becoming younger. This article reviews the related research on ACSL and breast cancer, and understands the exact role of ACSL in breast cancer and the molecular mechanism involved, which can provide ideas for finding new targets for breast cancer diagnosis and treatment and developing new strategies for gene therapy.

KEYWORDS

Long-Chain Acyl-CoA Synthetase, Breast Cancer, Fatty Acid, Molecular Mechanism, Prognosis

CITE THIS PAPER

Hua Liu, Jianfeng Quan, Research Progress of ACSLs and Breast Cancer. MEDS Clinical Medicine (2022) Vol. 3: 101-106. DOI: http://dx.doi.org/10.23977/medsc.2022.030617.

REFERENCES

[1] Stä ubert, C., et al., Hydroxycarboxylic acid receptors are essential for breast cancer cells to control their lipid/fatty acid metabolism. Oncotarget, 2015. 6(23): p. 19706-19720. 
[2] Menendez, J.A. and R. Lupu, Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer, 2007. 7(10): p. 763-77. 
[3] Ellis, J.M., et al., Acyl-coenzyme A synthetases in metabolic control. Curr Opin Lipidol, 2010. 21(3): p. 212-7. 
[4] Soupene, E. and F.A. Kuypers, Mammalian Long-Chain Acyl-CoA Synthetases. Experimental Biology and Medicine, 2008. 233(5): p. 507-521. 
[5] Zhan, T., et al., Overexpressed FATP1, ACSVL4/FATP4 and ACSL1 increase the cellular fatty acid uptake of 3T3-L1 adipocytes but are localized on intracellular membranes. PLoS One, 2012. 7(9): p. e45087. 
[6] Deng, Y., et al., Rab18 binds PLIN2 and ACSL3 to mediate lipid droplet dynamics. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2021. 1866(7): p. 158923. 
[7] Duarte, A., et al., Mitochondrial fusion is essential for steroid biosynthesis. PLoS One, 2012. 7(9): p. e45829. 
[8] Wu, X., et al., Baicalin inhibits PDGF-BB-induced hepatic stellate cell proliferation, apoptosis, invasion, migration and activation via the miR-3595/ACSL4 axis. Int J Mol Med, 2018. 41(4): p. 19922002. 
[9] Park, S., et al., Suppression of ABCD2 dysregulates lipid metabolism via dysregulation of miR141:ACSL4 in human osteoarthritis. Cell Biochemistry and Function, 2018. 36(7): p. 366-376. 
[10] Mashima, T., et al., Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Science, 2009. 100(8): p. 1556-1562. 
[11] Mashima, T., et al., Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene, 2009. 28(1): p. 9-19. 
[12] Lopes-Marques, M., et al., Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol Biol, 2013. 13: p. 271. 
[13] Chen, W., et al., Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLOS ONE, 2016. 11(5): p. e0155660. 
[14] Zhang, S., et al., Cancer incidence and mortality in China, 2015. Journal of the National Cancer Center, 2021. 1(1): p. 2-11. 
[15] Zhang Xue et al., Research progress on epidemiological trends and risk factors of female breast cancer. Vol. 48.2021.87-92. 
[16] Quan, J., A.M. Bode and X. Luo, ACSL family: The regulatory mechanisms and therapeutic implications in cancer. European journal of pharmacology, 2021. 909: p. 174397. 
[17] Thomas, R., et al., ACSL1 Regulates TNFα-Induced GM-CSF Production by Breast Cancer MDA-MB-231 Cells. Biomolecules, 2019. 9(10): p. 555. 
[18] Zhou, X., et al., The Clinical Significance of PR, ER, NF-κ B, and TNF-α in Breast Cancer. Disease Markers, 2014. 2014: p. 1-7. 
[19] Radif, Y., et al., The endogenous subcellular localisations of the long chain fatty acid-activating enzymes ACSL3 and ACSL4 in sarcoma and breast cancer cells. Molecular and Cellular Biochemistry, 2018. 448(1-2): p. 275-286. 
[20] Jeong, H.M., et al., Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. Oncotarget, 2017. 8(37): p. 61538-61550. 
[21] Maloberti, P.M., et al., Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells. PLoS One, 2010. 5(11): p. e15540. 
[22] Wang, M., K.V. Honn and D. Nie, Cyclooxygenases, prostanoids, and tumor progression. Cancer and Metastasis Reviews, 2007. 26(3-4): p. 525-534.
[23] Belkaid, A., R.J. Ouellette and M.E. Surette, 17β-estradiol-induced ACSL4 protein expression promotes an invasive phenotype in estrogen receptor positive mammary carcinoma cells. Carcinogenesis, 2017. 38(4): p. 402-410.
[24] Wu, X., et al,Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PloS one, 2013. 8(10): p. e77060. 
[25] Ulises Daniel Orlando, A.F.C.M., Acyl_CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochemical Pharmacology, 2019(159 ): p. 52-63 .
[26] Doll, S., et al., ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nature Chemical Biology, 2017. 13(1): p. 91-98. 
[27] Yen, M.C., et al., Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance. Oncol Rep, 2017. 37(6): p. 32533260. 
[28] Chen, W., et al., Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer. PLOS ONE, 2016. 11(5): p. e0155660. 
[29] Rossi Sebastiano, M. and G. Konstantinidou, Targeting Long Chain Acyl-CoA Synthetases for Cancer Therapy. International Journal of Molecular Sciences, 2019. 20(15): p. 3624. 
[30] Castillo, M.I., et al., Novel Variation in Acyl-CoA Synthetase Long Chain Family Member 6 (ACSL6) Results in Protein Structural Modification and Multiple Non-Related Neoplasia in a 46-YearOld: Case Report. Frontiers in Oncology, 2022. 12. 
[31] Song, H., et al., An integrated microfluidic cell array for apoptosis and proliferation analysis induction of breast cancer cells. Biomicrofluidics, 2010. 4(4): p. 44104.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4618
Visits: 200944

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.